Host: Rabbit
Target Protein: AF 4
IR: Immunogen Range:31-130/1210
Clonality: Polyclonal
Isotype: IgG
Entrez Gene: 4299
Swiss Prot: O88573
Source: KLH conjugated synthetic peptide derived from human AF 4:31-130/1210
Purification: affinity purified by Protein A
Storage: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
Background: Proto-oncogene AF-4 (or FEL) is a product of a chromosomal aberration of the human gene AFF1, which is associated with acute leukemias. The fusion of AF-4 on chromosome band 4q21 with the mixed lineage leukemia (MLL or HRX) gene on 11q23 results in a MLL-AF-4 chimeric transcription factor in which AF-4 contributes transcriptional effector properties and requires cell-specific accessory factors. MLL is involved in several chromosomal translocations associated with acute myeloid and lymphoid leukemia. The MLL-AF-4 fusion protein is expressed in all normal hematopoietic cells. The expression of MLL-AF-4 influences the production of protein cyclin-dependent kinase inhibitor (CDKN1B), suggesting that inhibition of MLL-AF-4 expression may be a powerful and highly specific treatment of chemotherapy-resistant leukemia.
Size: 100ul
Concentration: 1mg/ml
Applications: IHC-P=1:100-500, IHC-F=1:100-500, IF=1:100-500, ELISA=1:5000-10000
Cross Reactive Species: (predicted: Human,Mouse,Rat,Rabbit)
For research use only. Not intended for diagnostic or therapeutic use.